
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
Today's contract manufacturing organizations (CMOs) offer the latest in technology advanced equipment and innovative homegrown production processes.
almost 23 years ago
Big Pharma Works on Productivityalmost 23 years ago
Hyperthermophilic Microorganisms and USP Hot Water Systemsalmost 23 years ago
Electronic Information Systemsalmost 23 years ago
Segregation of Powders during Gravity Flow Through Vertical Pipes





